My research interests are focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and approaches for risk prediction, population stratification, targeted screening, cancer prevention and cost-effectiveness analyses.
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.